Stocks · News reference
Evotec Subsidiary Just Biologics Moves JST-018 Orthopoxvirus Antibodies Into First-In-Human Phase 1 Study For Biodefense
First-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies ProgramSupports development of countermeasures
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.
HC Wainwright & Co. Reiterates Buy on Evotec, Maintains $4 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evotec (NASDAQ:EVO) with a Buy and maintains $4 price target.
BIO-Europe 2026 to Convene Global Biopharma Decision-Makers in Cologne
BIO-Europe 2026 will host over 6,000 senior leaders from the global biopharma industry in Cologne, Germany, from November 9-11, 2026. The 32nd annual edition expands beyond partnering to become Europe's largest biopharma strategy forum, featuring seven integrated tracks covering regulatory, clinical, and manufacturing strategy, with focus on partnerships, innovation, and addressing industry challenges.